Compare CRNX & WRBY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRNX | WRBY |
|---|---|---|
| Founded | 2008 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Ophthalmic Goods |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.4B |
| IPO Year | 2018 | 2021 |
| Metric | CRNX | WRBY |
|---|---|---|
| Price | $84.78 | $26.21 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 11 |
| Target Price | ★ $76.75 | $27.10 |
| AVG Volume (30 Days) | 2.6M | ★ 2.6M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 105.88 |
| EPS | N/A | ★ 0.06 |
| Revenue | $1,039,000.00 | ★ $871,905,000.00 |
| Revenue This Year | $720.10 | $14.48 |
| Revenue Next Year | $184.67 | $16.41 |
| P/E Ratio | ★ N/A | $457.33 |
| Revenue Growth | N/A | ★ 13.04 |
| 52 Week Low | $30.00 | $14.96 |
| 52 Week High | $84.80 | $31.00 |
| Indicator | CRNX | WRBY |
|---|---|---|
| Relative Strength Index (RSI) | 89.98 | 48.05 |
| Support Level | $83.47 | $24.00 |
| Resistance Level | N/A | $27.59 |
| Average True Range (ATR) | 0.20 | 1.68 |
| MACD | -1.13 | 0.07 |
| Stochastic Oscillator | 98.98 | 27.14 |
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
Warby Parker Inc is a mission-driven, lifestyle brand that operates at the intersection of design, technology, healthcare, and social enterprise. The Company provides holistic vision care by offering eyewear, contacts, and eye care directly to consumers through its integrated, omnichannel platform. The company predominantly derives revenue from the sales of eyewear products, optical services, and accessories. The firm sells products and services through its stores, website, and mobile apps. Revenue generated from eyewear products includes the sales of prescription and non-prescription optical glasses and sunglasses, contact lenses, eyewear accessories, and expedited shipping charges.